Eduardo Vilar

8.9k total citations · 2 hit papers
106 papers, 4.8k citations indexed

About

Eduardo Vilar is a scholar working on Pathology and Forensic Medicine, Oncology and Cancer Research. According to data from OpenAlex, Eduardo Vilar has authored 106 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Pathology and Forensic Medicine, 62 papers in Oncology and 37 papers in Cancer Research. Recurrent topics in Eduardo Vilar's work include Genetic factors in colorectal cancer (65 papers), Cancer Genomics and Diagnostics (33 papers) and Colorectal Cancer Treatments and Studies (29 papers). Eduardo Vilar is often cited by papers focused on Genetic factors in colorectal cancer (65 papers), Cancer Genomics and Diagnostics (33 papers) and Colorectal Cancer Treatments and Studies (29 papers). Eduardo Vilar collaborates with scholars based in United States, Spain and Italy. Eduardo Vilar's co-authors include Stephen B. Gruber, Josep Tabernero, Scott Kopetz, Y. Nancy You, Miguel A. Rodrı́guez-Bigas, José Manuel Pérez-García, Kyle Chang, Cathy Eng, Patrick M. Lynch and Michael J. Overman and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Angewandte Chemie International Edition and Journal of Clinical Investigation.

In The Last Decade

Eduardo Vilar

99 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Microsatellite instability in colorectal cancer—the stable evidence

2010 734 citations Eduardo Vilar, Stephen B. Gruber profile →
Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer

2022 141 citations Eduardo Vilar et al. profile →

Peers

Eduardo Vilar

ONCOL

PFM

EPIDE

Anke Reinacher‐Schick Germany

Xavier Sagaert Belgium

Rebecca Elstrom United States

Richie Soong Singapore

Yun Wu United States

Yuankai Shi China

Tae‐You Kim South Korea

Mario Scartozzi Italy

Teresa Troiani Italy

Dongfeng Tan United States

Anke Reinacher‐Schick Germany

Eduardo Vilar

3.1k ×1.1

ONCOL

868 ×0.5

PFM

1.3k ×0.9

1.4k ×1.0

316 ×0.5

EPIDE

Citations per year, relative to Eduardo Vilar Eduardo Vilar (= 1×) peers Anke Reinacher‐Schick

Countries citing papers authored by Eduardo Vilar

Since Specialization

Citations

This map shows the geographic impact of Eduardo Vilar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eduardo Vilar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eduardo Vilar more than expected).

Fields of papers citing papers by Eduardo Vilar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eduardo Vilar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eduardo Vilar. The network helps show where Eduardo Vilar may publish in the future.

Co-authorship network of co-authors of Eduardo Vilar

This figure shows the co-authorship network connecting the top 25 collaborators of Eduardo Vilar. A scholar is included among the top collaborators of Eduardo Vilar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eduardo Vilar. Eduardo Vilar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Yihui, So‐Young Park, Jody V. Vykoukal, et al.. (2025). Citrullinated ENO1 Vaccine Enhances PD-1 Blockade in Mice Implanted with Murine Triple-Negative Breast Cancer Cells. Vaccines. 13(6). 629–629.

White, Michael G., John Paul Shen, Eduardo Vilar, et al.. (2025). Mutational and co-mutational landscape of early onset colorectal cancer. Biomarkers. 30(1). 64–76. 6 indexed citations

Vilar, Eduardo, Jason Willis, Michael J. Hall, et al.. (2024). 638 Nous-209 vaccine induces shared neoantigen immunogenicity for cancer interception in healthy lynch syndrome carriers: results from phase Ib/II trial. Regular and Young Investigator Award Abstracts. A732–A732. 1 indexed citations

Thomas, Jane V., Kaysia Ludford, Jason Willis, et al.. (2023). Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Research Communications. 3(12). 2510–2517. 4 indexed citations

Annapragada, Ananth, Andrew G. Sikora, Himangi Marathe, et al.. (2023). The Cancer Moonshot Immuno-Oncology Translational Network at 5: accelerating cancer immunotherapies. JNCI Journal of the National Cancer Institute. 115(11). 1262–1270. 2 indexed citations

Kambal, Amal, Hoa Nguyen‐Phuc, Sara C. Di Rienzi, et al.. (2023). Human intestinal organoids from Cronkhite-Canada syndrome patients reveal link between serotonin and proliferation. Journal of Clinical Investigation. 133(21). 8 indexed citations

Hodan, Rachel, Linda Rodgers, Sanjeevani Arora, et al.. (2023). Current chemoprevention approaches in Lynch syndrome and Familial adenomatous polyposis: a global clinical practice survey. Frontiers in Oncology. 13. 1141810–1141810. 6 indexed citations

Peacock, Oliver, et al.. (2022). Clinically Significant Metachronous Colorectal Pathology Detected Among Young-Onset Colorectal Cancer Survivors: Implications for Post-Resection Surveillance Guidelines. Gastroenterology. 163(6). 1682–1684.e2. 4 indexed citations

Parseghian, Christine M., Ryan Sun, Stefania Napolitano, et al.. (2022). Resistance Mechanisms to Anti–Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy. Journal of Clinical Oncology. 41(3). 460–471. 41 indexed citations

10.

Hodan, Rachel, Linda Rodgers, Sanjeevani Arora, et al.. (2022). Patterns of germline and somatic testing after universal tumor screening for Lynch syndrome: A clinical practice survey of active members of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. Journal of Genetic Counseling. 31(4). 949–955. 3 indexed citations

11.

Borràs, Ester, Wenhui Wu, Kyle Chang, et al.. (2021). Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis. Cancer Prevention Research. 14(9). 851–862. 10 indexed citations

12.

Rajendran, Praveen, Wan Mohaiza Dashwood, Michelle I. Savage, et al.. (2020). Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP). Cancer Prevention Research. 14(3). 325–336. 12 indexed citations

13.

Mork, Maureen E., Sarah A. Bannon, Patrick M. Lynch, et al.. (2019). Outcomes of disease-specific next-generation sequencing gene panel testing in adolescents and young adults with colorectal cancer. Cancer Genetics. 235-236. 77–83. 2 indexed citations

14.

Bannon, Sarah A., Maria F. Montiel, Jennifer B. Goldstein, et al.. (2018). High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer. Cancer Prevention Research. 11(11). 679–686. 32 indexed citations

15.

Borràs, Ester, Kyle Chang, Mala Pande, et al.. (2017). In Silico Systems Biology Analysis of Variants of Uncertain Significance in Lynch Syndrome Supports the Prioritization of Functional Molecular Validation. Cancer Prevention Research. 10(10). 580–587. 12 indexed citations

16.

Goldstein, Jennifer B., William Ka Kei Wu, Ester Borràs, et al.. (2017). Can Microsatellite Status of Colorectal Cancer Be Reliably Assessed after Neoadjuvant Therapy?. Clinical Cancer Research. 23(17). 5246–5254. 30 indexed citations

17.

Maletzki, Claudia, Ingrid Bauer, Tim Ripperger, et al.. (2017). Frameshift mutational target gene analysis identifies similarities and differences in constitutional mismatch repair‐deficiency and Lynch syndrome. Molecular Carcinogenesis. 56(7). 1753–1764. 11 indexed citations

18.

Crespo, Miguel, Eduardo Vilar, Su‐Yi Tsai, et al.. (2017). Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing. Nature Medicine. 23(7). 878–884. 293 indexed citations

19.

Vilar, Eduardo, Stephanie L. Stenzel, Leon Raskin, et al.. (2011). MRE11 Deficiency Increases Sensitivity to Poly(ADP-ribose) Polymerase Inhibition in Microsatellite Unstable Colorectal Cancers. Cancer Research. 71(7). 2632–2642. 117 indexed citations

20.

Vilar, Eduardo, Bhramar Mukherjee, Rork Kuick, et al.. (2009). Gene Expression Patterns in Mismatch Repair-Deficient Colorectal Cancers Highlight the Potential Therapeutic Role of Inhibitors of the Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway. Clinical Cancer Research. 15(8). 2829–2839. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact